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Summary.-A heteroantiserum raised in rabbits to extracts of human squamous-
cell carcinoma of the lung which exhibited marked tumour specificity was used
to monitor the fractionation and isolation of a tumour-associated component of the
extract. KCl extracts of pools of both normal lung and bronchogenic squamous-cell
carcinoma were subjected to a series of purification steps involving acid precipita-
tion, salting out, DEAE chromatography and preparative polyacrylamide-gel
electrophoresis. At each stage, fractions were tested for their ability to react in the
complement-fixation assay with the antiserum. A protein was ultimately isolated
which did not appear to be present at detectable levels in an equivalent fraction of
normal lung extract, reacted with the heteroantiserum, and appeared to be present
in all extracts of squamous-cell carcinoma.
SEVERAL investigators have reported
finding antigens common to various types
of human lung-cancer tissue (Yachi et al.,
1968; Mohr et al., 1974; Sega et al., 1974).
These observations, as well as early work
carried out in this laboratory (Watson
et al., 1975) were indicative rather than
conclusive that there might be common
tumour-specific components in broncho-
genic carcinomas.
More recently, we were able to present
more convincing data that a common
tumour marker could be detected immuno-
logically in human squamous-cell car-
cinoma of the lung (Kelly & Levy, 1977).
By using the principle reported some
years ago by Moller (1969) that the im-
mune response to a particular antigen
could effectively be suppressed by passive
immunization of the recipient animal at
the time of antigen challenge, we were
able to raise antisera in rabbits with a
marked degree of specificity for tumour
extract and only minor anti-normal-tissue
antibodyactivity. Basically, we found that
relatively specific anti-tumour antibody
could be raised by repeatedly immunizing
animals with a soluble mixture of tumour
extract and anti-normal-tissue extract
serum in the zone of antibody excess.
When the resulting antiserum, after a
single absorption, was tested by comple-
ment fixation against a panel of tissue
extracts, including a variety of tumour
extracts and normal tissue extracts, it
was found that, although there were
quantitative differences, all extracts of
squamous-cell carcinoma reacted posi-
tively, other lung tumour extracts (ana-
plastic, oat-cell, adenocarcinoma and
alveolar) gave positive reactions about
50% of the time, while all normal adult
tissue extracts were negative. Foetal lung
extract reacted weakly with the anti-
serum.
These data formed the basis for the
work reported herein, in which we
have attempted to purify biochemically
the tumour-associated component of
squamous-cell carcinoma. By using the
specific antiserum to monitor the activity
ofvarious fractions oftumour and normal
lung extracts, we have succeeded in
isolating a protein which appears to bePURIFICATION OF A TUMOUR-ASSOCIATED PROTEIN
a common marker for squamous-cell car-
cinoma, which is absent from normal
tissue, or present at concentrations that
areundetectable bythe methods used here.
MATERIALS AND METHODS
Tissue extracts.-Extracts of both normal
and tumour tissue were prepared as 30M
KCI extracts by the method described pre-
viously (Watson et at., 1975). Briefly, tissue
was homogenized and extracted in 30M
KCI for 24 h at 4C, after which it was centri-
fuged to remove particulate matter, dialysed
exhaustively against physiological saline, and
centrifuged again at 16,000 g for 90 min.
The extracts were stored at -20°C. For the
following experiments, normal extracts were
made from 12 pooled necropsy tissue speci-
mens of lung. Tumour tissues were obtained
at necropsy from the lungs of patients dying
from squamous-cell bronchogenic carcinoma.
A total of 7 individual tumour extracts were
pooled for the purposes of these experiments.
The protein concentration of each pooled
extract was determined by recording the
absorbance of samples at both 280 and
260 nm and applying the following formula
to these readings to obtain mg/ml: (280
absorbance x 156)-(260 absorbance x0.76).
Subsequent protein concentrations were cal-
culated accordingly.
Purification of extracts.-The following
procedures were carried out to fractionate the
KCI extracts.
1. Acid precipitation. The pH ofthe extract
was adjusted to pH 5.0 with I-OM acetate
buffer, pH 5 0. Precipitation was allowed to
take place for 18 h at 4WC, after which the
preparation was centrifuged at 20,000 g for
30 min. The supernatant was adjusted to
pH 7-5 with dilute NaOH, and the precipitate
dissolved in physiological saline. Both frac-
tions were dialysed against saline.
2. Salting out. The acid-soluble fraction
obtained above was subjected to further
fractionation by salting out with (NH4)2SO4.
Saturated (NH4)2S04 (SAS) was added slowly
to this fraction, with stirring, until the con-
centration reached 33% saturation. This was
left at 4WC for 18 h, after which the pre-
cipitate was removed by centrifugation, and
more SAS was added to the supernatant to
bring the concentration to 50% saturation.
The precipitate thus formed was removed
as above and the concentration of SAS was
brought to 90% saturation. All 3 precipitates
were dissolved in small volumes of physio-
logical saline, and exhaustively dialysed
against saline at 4C.
3. DEAE fractionation. The SAS cut of
33-50% saturation was subjected to further
purification on DEAE cellulose. Step-wise
elution was carried out on columns of DEAE
cellulose which had been equilibrated with
OOlM phosphate buffer at pH 7*5. Three
steps were used in this procedure; one with
the starting buffer, one with 0'05M phosphate
buffer at pH 7 5, and one with 0-2M phosphate
buffer at pH 7*5. The elution profiles obtained
by this method were monitored by the
absorbance of individual fractions at 280 nm.
Peaks were pooled and concentrated down to
about 5 0 ml using an Amicon UMIO ultra-
filter. Fractions were dialysed against saline
and stored frozen at -20W.
Immunization protocot.-The method used
to raise heteroantiserum to tumour extracts
has been described in detail elsewhere (Kelly
& Levy, 1977). Briefly, antiserum was raised
in rabbits to a KCI extract of pooled normal
lung. This antiserum was mixed, in antibody
excess, with an extract from a squamous-cell
bronchogenic carcinoma (C-71). This mixture
was used to raise antitumour serum in a
second rabbit. The presence of anti-normal
serum effectively suppresses the anti-normal
response in the second rabbit, so that the
antibody developing in this animal is largely
specific forthe tumour-associated components
of the antigen. This antiserum, after absorp-
tion, was used in the initial stages ofthe work
reported here, and is the same antiserum as
that reported on previously (Kelly & Levy,
1977).
When the DEAE-fractionated extracts
were tested for the presence of tumour-
specific materials, the material eli,¢ing from
DEAE with OOlM phosphate buffer was
noted to contain what appeared to be a major
antigenically active component. This fraction
was also used for the preparation of specific
antiserum by the method mentioned above.
In this instance, the equivalent DEAE
fraction from normal lung extract was used
to immunize the first rabbit, and this anti-
serum was mixed with the tumour extract
DEAE fraction to raise tumour-specific
antiserum in the second rabbit. This anti-
serum was used in all tests carried out in the
later stages of purification (involving elution
of antigens from PAGE) after absorption on
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an immunoadsorbent column prepared with
the equivalent normal DEAE fraction (see
below).
Immunoadsorbents.-The antiserum raised
against the whole tumour extract was
absorbed on a glutaraldehyde-insolubilized
preparation ofnormal lung extract, according
to the method ofAvrameus & Ternyck (1969)
with modifications described previously(Kelly
& Levy, 1977). The second antiserum, raised
against a fraction of the tumour extract, was
absorbed on a solid-phase Sepharose 4B
cyanogen bromide linked column containing
the equivalent fraction ofnormal lung extract.
The method used was based on the procedures
described by Porath et al. (1967). The
immunoadsorbent contained 6-0 mg ofprotein
per ml of beads.
Complement-fixation assay.-The presence
of tumour-associated components in various
fractions was detected by a standard com-
plement-fixation assay. Details of this pro-
cedure have been described previously (Kelly
& Levy, 1977). In the interpretation of the
data reported here, C'H* 50 Ag-Ab values
below 0-2 were not considered to be sig-
nificant, and the data reported involved the
use of optimal antigen levels, since antigen
was usually titrated over a range of 100 to
6 Hug/ml, depending on the sample.
Isoelectricfocusing.-Preparative isoelectric
focusing was performed on Fraction I
materials from DEAE chromatography.
Focusing was carried out at 4°C in a l1lOml
LKB column using LKB ampholines at
1-2% over a broad pH range (3 5-10).
A light gradient solution (500) was made
before each run containing 2-7 g sucrose,
1-4 ml Ampholine pH 3 5-10 (LKB 1809-
101), 0-2 ml Ampholine pH 4-6 (LKB 1809-
116), 0-2 ml Ampholine pH 5-7 (LKB 1809-
121), 46-0 ml H20 and 4-5 ml sample. A dense
gradient solution (5000) was made to con-
tain 27-0 g sucrose, 1-4 ml Ampholine pH
3 5-10, 0 4 ml Ampholine pH 9-11 (LKB
1809-146), 27-7 ml H20 and 4-5 ml sample.
Samples of Fraction I material contained
1 mg/ml protein. A linear sucrose gradient
was made by using a Pharmacia pump. The
current for focusing was supplied by a
Buchler constant-voltage power supply. In-
creases of 100 V were made every 30 min
until maximum voltage of 900-1000 V was
reached. Focusing was allowed to continue
for 48 h, at which time the current approxi-
mated 1.0 mA, indicating that the pH
gradient had been formed. At the end of the
run, the column was pumped out and frac-
tions of 1 0 ml were collected on an LKB
fraction collector at 40 sec per tube. Readings
of pH (at 4°C) and optical density (at
280 nm) were made on each fraction. Tubes
containing distinct protein peaks were pooled
and exhaustively dialysed against saline at
4°C. These fractions were subsequently tested
for antigenic activity by complement fixa-
tion.
Acrylamide-gelelectrophoresis.-Themethod
used here for preparative slab polyacryla-
mide-gel electrophoresis (PAGE) was based on
the procedure of Laemmli (1970). Running
gels (10 cmxl4 cmx2 mm) containing 1000
acrylamide and 0-1% SDS were overlayed
with 3 cm ofstacking gel. Fraction I materials
from DEAE chromatography were dialysed
into the electrophoresis glycine-SDS running
buffer. An aliquot (2.5 mg in 0 5 ml) contain-
ing glycerol and tracking dye (bromphenol
blue) was applied to the gel surface and run
into the stacking gel for 30 min with a current
of 15 mA. At this time, the current was
increased to 25 mA for 2 h, followed by an
increase to 50 mA for another 2 h. All gels
were run at 4°C. At the end of the electro-
phoresis the gel was quickly removed and a
2cm slice cut off from one end. This slice
was stained with Coomassie brilliant blue
(0.25%) in methanol:acetic acid :water
(5:1:5) overnight and subsequently destained
in the same solvent. The gel was finally
swollen to its original size in 70o acetic acid.
The remainder of the gel was sliced horizon-
tally into 3mm strips, which were individu-
ally placed in 4 ml saline and left to elute
overnight at 4°C. The eluted fractions were
dialysed for 4-5 days against frequently
changed saline. Protein concentrations were
determined on the resulting fractions, which
were then set up in complement-fixation
assays to determine antigenic activity. A
number of gels were similarly run, and those
fractions in a particular area ofthe gel which
were shown by complement-fixation to be
antigenically active werepooled, concentrated
by Amicon Diaflo filtration with a UMIO
membrane, and re-run as described to further
improve the resolution. Initially the gels
were run for 3 h. However, the antigenically
active areas ofthe gel were found to be in the
top 3 portion ofthe gel, and so it was decided
to increase the running time to 6 h in order
to enhance separation. In our hands, these
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procedures did not appear to alter the anti-
genic integrity of the materials we were
testing.
Analytical acrylamide gels were set up and
run as described above. Samples of 50-100 jug
protein in 25 1l and containing glycerol and
tracking dye were applied to individual wells
in the gel. Electrophoresis was allowed to con-
tinue for 3 h or until the tracking dye reached
the bottom of the gel, whereupon the gel was
fixed and stained as described.
Gradient acrylamide-gel electrophore8is.-
Protein fractions isolated from acrylamide-gel
electrophoresis were iodinated according to
the chloramine-T method of Greenwood et al.
(1963). Aliquots (10 jtg) of those fractions
from tumour and normal extracts which
previously had been shown to be antigenically
active in the complement fixation assay were
reacted with 0-25 mCi of 1251 (New England
Nuclear, Dorval, Quebec). The labelled frac-
tions were exhaustively dialysed against
distilled H20 until the radioactive counts in
the dialysate were down to background levels.
The resulting specific activities were 1 05 x
108 ct/min/mg protein for the tumour fraction
and 6-5 x 107 ct/min/mg protein for the
normal fraction. These relatively low specific
activities are attributable to the low protein
concentration in the iodinated preparations.
Aliquots of the iodinated fractions of
tumour and normal extracts were then run on
a commercially prepared gradient gel (Phar-
macia gradient gel PAA 4/30) in a TRIS
(0 09M):borate (0-09M)EDTA (0-003M) buffer
system at pH 8-35. The gel was pre-run for
15 min at 125 V. The samples were applied
and the gel was pre-electrophoresed for 20
min at 70 V. Running time for the electro-
phoresis was 16 h at 120 V. On termination of
the electrophoresis, the gel was quickly
frozen at -70°C. Serial slices of gel 1 mm
thick were made from those areas ofthefrozen
gel containing electrophoresed material, using
a Mickle gel slicer (Brinkman Instruments).
Individual slices were counted in a gamma
counter (Biogamma) for 10 min per slice.
Molecular-weight assessments were made by
comparing samples to the standards set up by
Pharmacia.
RESULTS
The extracts prepared from pooled
normal human lung (N-lung) or broncho-
genic squamous-cell carcinoma tissue (C-
lung) were subjected to fractionation,
first with acid precipitation followed by
fractional precipitation at 33, 50 and 90%0
saturation with (NH4)2S04. Each fraction
thus obtained was tested by complement
fixation with antiserum directed mainly at
tumour-unique antigenic components. Re-
sults of these tests are summarized in
Table 1. There are several points to make
TABLE I.-Antigenic activity of various
fractionsofN-lungand C-lungasassessed
by complementfixation
AMaterial tested
Unfractionated extract
Acid-precipitated material
Acid-soluble material
Acid-soluble material
precipitated with
(NH4)2S04:
33% saturated
50% saturated
90% saturated
C'H*50
Antigen (Ag+Ab)
level , X
(pg/ml)I N-lung C-lung
160 0-63 1-88
402 0 0-38
160 0-25 1-13
20
20
20
0-88 0-75
0-50 1-63
0-63 0-38
lAntigen levels giveni are those in the individual
titrations with maximal reactivity.
2Not testable at higher levels because of marked
non-specific anti-complementary effects.
about these observations and this assay
system. The antiserum used here, although
it had been absorbed with normal tissue
extracts, usually gave low levels of reac-
tivity with N-lung preparations. Also, the
test is subject to fluctuation in absolute
number values (complement-fixing units)
from one day to the next, due, no doubt,
to the variables associated with the
complement-fixation test. Therefore, tests
on N- and C-lung fractions were always run
concurrently with antigen and antibody
controls, so that the relative reactivity
of equivalent samples could be assessed.
On this basis, selections were made of
which fractions to purifyfurther. As shown
in Table I, the acid-soluble fraction con-
tained essentially all the reactivity of the
original unfractionated extracts, so it
was subjected to further fractionation
with (NH4)2SO4. Because the 33-50/O-
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FiGc. 1.-Elution proffle resulting from step-
wise elution of either normal lung or
tumour KCI extracts. Breaks indicate
stepwise changes in buffer concentration as
follows (from the left): '0O1M P04, 0-05M
P04 and 0-2M P04. The pH was maintained
at 7-5.
saturation precipitate showed the greatest
antigenic reactivity, it was chosen as the
material for further fractionation. The
amount of protein in this fraction rep-
resented 10-14% of the original protein
material. It is possible that the reactivities
seen in the other tumour fractions could
represent other components to which the
antisera reacted, or they could represent
the apparently major component in other
forms or associated with other proteins.
This material (the 33-50% (NH4)2SO4
precipitable) was subjected to chromatog-
raphy on DEAE cellulose with a stepwise
elution procedure. A typical elution profile
for the tumour extract is shown in Fig. 1.
These 3 fractions and equivalent fractions
from N-lung were concentrated and tested
for antigenic activity by complement
fixation. The elution profile for N-lung
material was essentially identical to that
for C-lung. A summary of the results is
shown in Table II. It can be seen that,
while both Fractions I and II from the
DEAE run demonstrated appreciable anti-
genic activity, there was a greater dif-
ference between the equivalent normal
and tumour Fraction I materials. For this
reason these materials were chosen for
further purification. The DEAE Fraction
I chromatographed material represented
-4°/% of the original protein concentra-
tion.
Because all further work was to be
carried out on C-lung I and N-lung I, it
was decided that an appropriate antiserum
to C-lung should be prepared and used in
subsequent tests. Accordingly, antiserum
to N-lung I was raised, mixed with C-lung
I and used to immunize a second rabbit.
This antiserum (anti-C-lung) was passed
through an immunoadsorbent column
prepared with N-lung I to try to remove
anti-normal activity.
The C-lung I material was subjected to
preparative isoelectric focusing. The eluted
material was fractionated according to
apparent protein peaks. Individual frac-
tions were dialysed, concentrated, and
titrated for antigenic activity. The results
of these tests showed that the active
material focused between pH 8a1 and
9 0. However, the results of complement-
TABLE II.-Antigenic activity of DEAE-fractionated material from N-lung
and C-lung assessed by complementfixation
Material tested
33-50% saturated (NH4)2SO4
fraction
DEAE-Fraction I
DEAE- Fraction II
DEAE-Fraction III
Antigen % original
levell material
(ltg/ml) (mg protein)
100
100
100
100
10-14
4-0
C'H*5o(Ag+Ab)
hA
N-lung C-lung
0-25 1-63
0-38 3-25
1-25 1-88
0-75 0-63
1 Those levels gave maximal complement fixation with the anti-C-71 serum used here.
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FiG. 2.-Complement-fixingcapacity ofindividual PAGE fractions withheteroantiserum. The tumour
extract, represented by the solid bars, invariably showed two areas of antigenic specificity, whereas
the N-lung fraction (clear bars), only showed one. All fractions were tested at 15 {tg/ml (optimal
concentration) with the antiserum prepared to C-lung DEAE-I. Fractions 5-7 were pooled in both
instances for further purification. Representative acrylamide sections are shown below in the graph.
It can be seen that the apparent tumour-specific component is present inthe trailingend ofthe major
heavy band in the gel. Electrophoresis runs in this instance lasted 6 h.
fixation assays ofthis material and DEAE
I fraction showed that we had not achieved
any marked degree of purification (Table
III). This method was not therefore used
in further purifications.
When preliminary preparative slab
acrylamide electrophoresis was performed
on C-lung I, the antigenically active
material appeared to be in a heavily
staining band of material of apparently
high mol. wt. It was decided to use slab
acrylamide electrophoresis in a preparative
manner, run it for 6 h, slice and elute, and
test the various fractions for antigenic
activity. A series of such runs were made,
all of which yielded similar results. While
the N-lung I preparations uniformly
yielded a single peak of reactive material,
I6m I I
t Lm 6i
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TABLE III.-Antigenic activity of DEAE-I
material comparedwithmaterial isoelectric
focusing at pH 8.1-9.0 from N-lung and
C-lung, as assessed by complement fixation
Material tested
DEAE- I
Focused material
(pH 8 1-9-0)
Antigen
level
( og/ml)
25
C'H* o (Ag+Ab)
N-lung C-lung
0-13 0-50
25 0-13 0-63
antigenic activity was bimodal in the C-
lung material, indicating the presence of
at least 2 antigenic components. These
results, correlated with the complement-
fixation results from the various acryla-
mide fractions, are shown in Fig. 2 for
both normal and tumour materials. It
appears that the tumour-related com-
ponent moved at the trailing end of the
heavily staining material.
In an attempt to purify this material
further, all acrylamide fractions containing
it were pooled, concentrated, and re-run
on acrylamide. Equivalent material from
N-lung acrylamide fractions was handled
in a similar way. The slabs were sliced
and eluted, and aliquots of each fraction
tested for antigenic activity. An active
fraction from the C-lung preparation was
thus isolated. The final electrophoretic
gels contained only one band detectable
by autoradiography, that in the C-lung
preparation, although it is probable that
there were small amounts ofother proteins
present. Equivalent fractions of the N-
lung preparation contained no detectable
antigen.
In order to determine whether this
fraction indeed contained protein unique
to tumour tissue, it and the equivalent
N-lung fraction were iodinated and run
on a gradient acrylamide gel. Areas of the
gel containing electrophoresed material,
either normal or tumour, were sliced and
the individual slices counted. The results
are in Fig. 3. It can be seen that the major
peak of radioactivity in the C-lung gel
(Fractions 45-50) has no equivalent in
the N-lung gel. The mol. wt ofthis fraction
was estimated to be 100,000 according
c
UE
10 20 30 40 50 60 70
FRACTION NO
FIG. 3. Ct/min recorded for 1mm slices
of the gradient gel run on 1251-labelled
material from previously electrophoretic-
ally purified samples of N-lung and C-lung.
The major peak for C-lung material
(0 0*), (Fractions 45 50) has no
counterpart in the N-lung material
(0 0)-
to the calibration standards outlined for
thedesignated Pharmaciagradientgelused
here. This final product constituted less
than 0 1%0 of the starting material,
although its original concentration was
probably higher, since the procedures used
here involved considerable loss of protein.
DISCUSSION
Preliminary fractionation procedures
carried out on the C-lung and N-lung
extracts (acid fractionation, salting out
and DEAE chromatography) showed that
it was possible to enrich for a component
in the C-lung extract which reacted
strongly with our antiserum (anti-C-71)
while yielding low levels of reactivity
with the equivalent N-lung fractions
(Tables I and II). This enrichment was
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not total, as lower levels of reactivity
were found in other fractions. Materials
for further study were selected on the
basis of a tumour fraction which contained
high levels of reactivity with the anti-
serum while the normal equivalent frac-
tion contained very little. Thus the DEAE-
fraction I (DEAE-I) material was chosen
for further study rather than Fraction II,
though considerable reactivity was found
in both fractions (Table II).
The decision to attempt to analyse
further only one of the DEAE cuts was to
some extent pragmatic. We are aware that
the material detected in DEAE Fraction
II could represent other components
specific for tumour tissues, incomplete
separation of the same component by the
fractionation procedure, or a degradation
product of the component in Fraction I.
However, since the greatest activity was
observed in Fraction I, this was selected
for further study. It is possible that the
use of necropsy material contributed to
this apparent heterogeneity. However,
since we were unable to obtain normal
lung tissue except at necropsy, it was
considered appropriate to use only nec-
ropsy material as the source of tumour
material to provide adequate controls. It
is also possible that the use of KCI
extraction (which has been reported to
activate proteolysis) as the primary step
for antigen extraction, could have con-
tributed to some degradative processes
and caused some of the apparent hetero-
geneity. These extraction procedures were
carried out at 4°C to minimize this
possibility, and were used because early
studies in extraction procedures had
demonstrated that 30M KCI was the most
efficient method for removing proteins
from cell homogenates. The observation
that the isolated material had a mol. wt
t100,000 indicates that it is probably
not markedly degraded as a result of our
procedures.
Because the SDS PAG(E analysis had
indicated that the majority of the com-
ponents were of relatively high mol. wt
(100,000) and did not penetrate very
16
far into the gel, further attempts at
purification of the tumour-specific marker
involved prolonged slab electrophoresis
(in order to separate further bands moving
similar distances) folloxved by elution of
strips and subsequent testing ofindividual
cuts for reactivity with the antiserum.
The results of these experiments indicated
that a fraction had been isolated from
C-lung by this procedure, which reacted
specifically with the antiserum and for
which there was no equivalent counterpart
in the N-lung fractions (Fig. 2). This
appeared to be a component at the trailing
end of the major heavily staining area on
the gels. These fractions from C-lung (and
the equivalent N-lung fractions) were
concentrated, re-run on PAGE slabs,
eluted, and tested for reactivity with the
antiserum. This second run enabled us to
obtain a discrete reaction from the C-lung
PAGE which reacted with the test
antisera (it reacted with both anti-C-71
and the antiserum prepared specifically
to C-lung DEAE-I). There was no such
fraction in the N-lung cuts. When this
material and the equivalent N-lung cuts
were iodinated, run on a gradient acryla-
mide gel, and serial slices from each were
measured for radioactivity, only the C-
lung preparation had a detectable peak in
the gel (Fig. 3).
There have been a number of reports
in the literature of tumour-specific anti-
gens associated with carcinoma of the
lung. Yachi et al. (1968) prepared xeno-
antisera to lung carcinoma saline extracts
which were soluble in 50 -saturated
(NH4)2SO4, and observed immunoprecipi-
tin lines with lung tumour extracts, one
of which cross-reacted with foetal lung
material. In our studies, we found origin-
ally that our antisera reacted wveakly with
foetal lung extracts (Kelly & Levy, 1977)
but have no evidence at present that the
partially characterized material reported
here is a foetal component. That Yachi
et al. found their material to be present
in the 5000-saturated (NH4)2SO4-soluble
fraction is not in agreement with our
findings, where most of our activity was
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found in the 33-50 0-saturation cut.
However, since their extraction proce-
dures differed from ours, it is possible
that the salting-out properties of the
antigens could also have differed. Viza
et al. (1975) used papain- digested extracts
of lung tumour tissue to immunize rabbits
and goats. These antisera were tested
after absorption against a variety of
lung tumour extracts of various histo-
logical origins, as well as a variety ofother
tumour extracts. They found a degree of
cross-reactivity (by immunodiffusion) with
other lung tumours, but none with other
tumour types or normal tissues. The
findings of these workers are in partial
agreement with those published by us
earlier (Kelly & Levy, 1977). While these
authors found only some cross-reactivity
with the autologous tumour type, we
reported positive reactions with all
squamous-cell carcinoma extracts tested.
It should be pointed out that we were
using a complement-fixation assay, as
opposed to immunodiffusion, and the
former method is considerably more
sensitive than the latter. Bell (1976) used
sonicated homogenates of normal, foetal
and tumour tissue to produce antisera in
rabbits to either adenocarcinoma or oat-
cell carcinoma extracts. The antisera were
absorbed and tested by immunodiffusion
against a variety of tissues. He observed
a degree of cross-reactivity between lung
tumours ofvarying histology. It is difficult
to compare these observations with the
findings reported here. The material we
isolated was clearly present in very low
concentrations in lung tissue. At no time
did our antisera, prepared by methods
altogether different from those described
by others, show any positive immuno-
diffusion patterns, even when partially
purified material was tested, although it
did show a marked degree of specificity
for tumour material. Further work is
needed before any critical comparisons
can be made between the component
isolated here, and materials detected by
others by immunodiffusion.
Our knowledge on the nature of this
apparent tumour-associated marker is as
yet preliminary. It is protein in nature,
has a mol. wt 100,000 and an isoelectric
point between 841 and 9 0. It appears
tohave anelectrophoretic mobility, charge,
isoelectric point and size very similar
to a group ofproteins found in normal lung
tissue. Whether or not this protein is a
traditional tumour-specific transplanta-
tion antigen (TSTA) or tumour-associated
antigen (TAA) or whether it is an antigen
of the human host remains to be clarified.
At this stage we conclude that this protein
is a component ofsquamous-cell carcinoma
which does not occur at detectable levels
(by our methods) in normal lung tissue,
and that it can be distinguished immuno-
logically from normal tissue components
by heteroantiserum raised in rabbits.
However, it is possible that this component
exists in normal tissue at levels below our
present detection capability at this time,
and no claims are made that it is unique
to tumour tissue. WVe can further conclude
that this component is present in essen-
tially all squamous-cell carcinoma ex-
tracts, since we used a number ofdifferent
tumour extracts, each being made from
pools of tumour tissue from different
individuals. At no time did we find that
levels of this material differed radically
from one batch to another. It therefore
appears to be worth while to investigate
this component further for its potential
diagnostic value.
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